After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Allogene Therapeutics Inc is $585.51M. A total of 2.37 million shares were traded on the day, compared to an average of 2.70M shares.
In the most recent transaction, Douglas Earl Martin bought 28,310 shares of ALLO for 2.79 per share on Aug 21 ’24. In a previous transaction on Jun 18 ’24, MESSEMER DEBORAH M. sold 18,641 shares at 2.28 per share. ALLO shares that Director owns now total 166,765.
Among the insiders who sold shares, Humer Franz B disposed of 11,200 shares on May 30 ’24 at a per-share price of $2.34. This resulted in the Director holding 255,253 shares of ALLO after the transaction. In another insider transaction, Belldegrun Arie bought 1,724,137 shares at $2.90 per share on May 16 ’24. Company shares held by the Director now total 1,724,137.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, ALLO has a high of $5.78 and a low of $2.01.
As of this writing, ALLO has an earnings estimate of -$0.32 per share for the current quarter. EPS was calculated based on a consensus of 17.0 estimates, with a high estimate of -$0.26 per share and a lower estimate of -$0.39. The company reported an EPS of -$0.37 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $47.91M in liabilities at the time. Its Book Value Per Share was $2.46, while its Total Shareholder’s Equity was $925.20M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.39.
